Introduction
============

Comorbid symptoms of anxiety and depression are common in patients with chronic obstructive pulmonary disease (COPD) ([@b54-copd-3-727]) and cause a number of negative effects. Compared with non-depressed COPD patients, COPD patients with elevated depression scores show lower health-related quality of life ([@b37-copd-3-727]; [@b54-copd-3-727]; [@b40-copd-3-727]), a lower level of functioning ([@b30-copd-3-727]), longer and more frequent hospital stays ([@b40-copd-3-727]), and increased mortality, as shown in prospective studies ([@b7-copd-3-727]; [@b40-copd-3-727]). Similarly, increased levels of anxiety lead to impairment of quality of life ([@b30-copd-3-727]; [@b11-copd-3-727]) and more frequent hospital admissions in COPD patients ([@b20-copd-3-727]; [@b53-copd-3-727]). However, the reported prevalence rates for comorbid symptoms of depression or anxiety are highly variable: in studies using anxiety and depression self-report questionnaires, these rates range from 13% and 7% ([@b16-copd-3-727]) to 96% and 79%, respectively ([@b3-copd-3-727]; [@b25-copd-3-727]). The few studies that assessed categorical diagnoses by means of international diagnosis systems such as the ICD-10 ([@b51-copd-3-727]) or the DSM-III-R/-IV ([@b43-copd-3-727]) also reported inconsistent but lower prevalence rates, ranging from 10% to 35% and 16% to 47%, respectively ([@b52-copd-3-727]; [@b28-copd-3-727]; [@b1-copd-3-727]; [@b2-copd-3-727]; [@b46-copd-3-727]). However, the generalization of these results is limited by the small sample sizes and the absence of control groups.

The inconsistency of previous findings may partly be due to varying inclusion criteria (eg, COPD grade 1--4, out-patients versus in-patients, stable or with exacerbation, with or without oxygen therapy) research strategies, and employed instruments. The use of screening questions that are highly sensitive to detect symptoms of anxiousness and dysphoria generally result in an extremely high proportion of individuals screened positive ([@b32-copd-3-727]). In contrast, self-report questionnaires assessing levels of symptomatology result in a smaller proportion of potentially disordered individuals. The presence of a clinically significant mental disorder, however, can be determined only on the basis of categorical diagnostics according to international classification systems such as the ICD-10 ([@b51-copd-3-727]). These diagnoses are based on a defined set of symptom criteria. Precise case definition criteria for each symptom (severity, frequency, duration) as well as explicit inclusion and exclusion criteria usually result in high inter-rater reliabilities. Thus, categorical diagnostics can be considered the gold standard in diagnosing mental disorders. Overall, though, few studies have employed such elaborate classification systems of mental disorders, and even fewer have compared their results with those of control groups (eg, [@b1-copd-3-727]; [@b34-copd-3-727]).

It is well documented that spouses of patients with other severe and life-threatening somatic diseases may encounter comparable psychosocial and emotional distress as the patients themselves. However, very few COPD studies have addressed this issue ([@b30-copd-3-727]; [@b26-copd-3-727]; [@b41-copd-3-727]). In two studies, the spouses of COPD patients reported levels of loneliness and depressive mood comparable to the levels reported by the patients themselves ([@b29-copd-3-727]; [@b27-copd-3-727]). To our knowledge, there have been no studies on the prevalence of mental disorders in spouses of COPD patients, even though their state of health may be of particular importance for the supportive care of patients.

The first purpose of the present study was to compare the prevalence of mental disorders in COPD patients with the prevalence in two reference groups of elderly persons. The second purpose was to investigate the prevalence of mental disorders in the spouses. Specifically, we examined the following questions: (1) Does the psychopathology of the patients and that of their spouses correlate with the health-related quality of life of the patients? (2) How is the COPD-related disability of spouses related to clinical variables of patients?

Methods
=======

Measures
--------

First, a bodyplethysmography (MasterScreenBody by Viasys/Jaeger) was performed, in accordance with the American Thoracic Society guidelines, as well as a shuttle walking test ([@b45-copd-3-727]; [@b14-copd-3-727]). The subjects performed only one test at baseline. Three to 10 days later, psychological diagnostics were carried out in the homes of the COPD patients by a clinical psychologist (Kerstin Kühl), who was blind to the results of lung function testing. At the beginning of the home assessment, patients and their spouses underwent a screening interview to assess for the presence of cardinal symptoms of depressive disorders (ICD-10 diagnosis of depressive episode \[F32\] or recurrent depressive disorder \[F33\]), dysthymia, panic disorder, agoraphobia, generalized anxiety disorder, as well as nicotine and alcohol abuse. For participants screened positive, categorical diagnostics (International Diagnostic Checklists for ICD-10) ([@b21-copd-3-727]) were used. Subsequently, the following questionnaires were applied:

The St. Georges Respiratory Questionnaire (SGRQ) (German version: [@b24-copd-3-727])
------------------------------------------------------------------------------------

The SGRQ assesses the subjective quality of life of COPD patients. Thus it cannot be rated by the spouses.

COPD Disability Index (CDI)
---------------------------

In contrast, COPD-related disability assessing reductions of social functioning and self-care can be rated both by patients and their spouses. The CDI is an adaptation of the Pain Disability Index (PDI) ([@b12-copd-3-727]). The original version comprises 7 items: family/home, responsibilities, recreation, social activity, occupation, sexual behavior, self-care, and life-support activities (breathing, sleeping, eating). For the purpose of the present study, item 7 (breathing, sleeping, eating) was limited to breathing. Since COPD is a respiratory disease, breathing, eating, and sleeping are affected differently and thus cannot be averaged in this study population. The degree of disability caused by the disease is rated on an 11-point rating scale for all respective aspects of life. In general, factor analyses with different patient groups and with spouses of pain patients have yielded one factor and confirmed the unidimensionality of the construct ([@b12-copd-3-727]), although there have been two exceptions ([@b48-copd-3-727]; [@b47-copd-3-727]). Spouses were instructed to evaluate their perceived disability due to their partner's illness.

The European Quality of Life Questionnaire (EuroQol) ([@b44-copd-3-727])
------------------------------------------------------------------------

The EuroQol assesses the generic health-related quality of life by means of a visual analogue scale. The scale ranges from 0 ("the worst state of health to be imagined") to 100 ("the best state of health to be imagined").

The Symptom-Checklist-90-R (SCL-90-R) ([@b19-copd-3-727])
---------------------------------------------------------

The SCL-90-R assesses physical and psychological symptoms within the last week. Only subscales that are relevant for the issue under investigation (depression, anxiousness, phobic anxiety, somatization) were included in the analysis. Two items of the somatization scale (chest pain and breathing difficulties) were excluded, since these symptoms might reflect actual symptoms of COPD rather than symptoms of psychopathology.

Statistical analysis
--------------------

The data was analysed using SPSS (v. 15.0. SPSS Inc., Chicago, IL). Internal consistency for the modified COPD-Disability-Index (CDI) was determined using Cronbach's alpha. Of particular note was the high internal consistency in the CDI (P-CDI = 0.92; S-CDI (without item 7 breathing) =0.86) (For reasons of clarity, variables assessed on COPD patients and their spouses will be labeled with P \[for COPD patients' data\] and S \[for spouses' data\].)The significant Pearson correlations between COPD-related disability (P-CDI) and the SGRQ in patients (SGRQ-S r = 0.59; SGRQ-A r = 0.74; SGRQ-I r = 0.81; SGRQ-T r = 0.83; all p \< 0.01) support the convergent validity of this new instrument. In addition, the significant associations between COPD-related disability in the spouses (S-CDI) and the SGRQ in the patients (SGRQ-S r = 0.35; SGRQ-A r = 0.45; SGRQ-I r = 0.59; SGRQ-T r = 0.56; all p \< 0.01) not only highlight the relationship between patient's health and partner's disability, but confirm that the CDI is a very short but nonetheless reliable and valid instrument.

The results of our patient and spouse samples will be compared with normative data of two representative samples of elderly persons ([@b50-copd-3-727]; [@b49-copd-3-727]). Comparisons for patients with and without mental disorders were computed by means of t-tests for independent samples and chi square tests. For nonparametrical variables Mann-Whitney U-test were analysed. Recent research (eg, [@b4-copd-3-727]; [@b8-copd-3-727]; [@b11-copd-3-727]; [@b40-copd-3-727]) has highlighted nine variables (FEV~1~, walking distance, gender, heart disease, somatization, anxiousness, depression (SCL-90-R), phobic anxiety (SCL-90-R), depression/anxiety diagnoses) as relevant predictors of health-related quality of life in patients with COPD. These variables were included in a stepwise multiple linear regression to predict patients' health-related quality of life (SGRQ). Furthermore, the part of explained variance of the COPD-related disability of the spouses (S-CDI) was calculated.

Patient sample
--------------

Over a period of 9 months, all COPD patients of a private pulmonary practice were consecutively asked if they wanted to take part in the study. Patients with a severity grade of 2, 3, or 4 (according to the GOLD criteria) who had been at the routine appointment 3 respectively 6 months before were included. All participants received €10 and a small present (candy) as reimbursement for their participation. Exclusion criteria were, for patients, illness exacerbation within the previous month or, for patients and spouses, a severe acute illness (such as myocardial infarction, tumor) within the last year. Of the 165 COPD patients who were approached, only 15 (9.1%) declined to participate. Ten participants -- 7 patients (4.2%) and 3 spouses (2.7%) -- had to be excluded for reasons of illness exacerbation (2), diagnosis of tumor (3), psychosis (1), missing data (1), possible dementia (2), or insufficient language abilities (1). Another couple was excluded from the comparison of couples because both were COPD patients. Thus, 143 COPD patients (and 105 spouses) were included in the analysis. The duration of illness was less than one year in 4.6% of patients, 1--3 years in 12.8% of patients, 3--10 years in 12.8 % of patients, and more than 10 years in 50.5% of patients. Within 12 months prior to the study, 15 patients (10.5%) had been admitted to hospital due to COPD exacerbation and two (1.4%) to a comprehensive pulmonary rehabilitation.

Results
=======

Comorbid mental disorders
-------------------------

Most of the 143 COPD patients (80.4%/75.2% of the spouses) did not fulfil the criteria of any of the investigated depressive or anxiety disorders ([Table 2](#t2-copd-3-727){ref-type="table"}).

COPD patients and their spouses were compared with a representative German aging study, which also used categorical diagnoses ([@b50-copd-3-727]). The prevalence rates for anxiety and depressive disorders (except for dysthymia) were higher than in the reference sample for both patients and their spouses (see [Table 2](#t2-copd-3-727){ref-type="table"}). Only five out of these 29 patients were taking psychotropic medication and no patients were receiving any form of psychological support or psychotherapeutic treatment. The prevalence of anxiety or depressive disorders was not influenced by COPD severity (grade 2 = 23.6%; grade 3 = 26.5%; grade 4 = 18.2%; χ^2^ = 0.23, df = 2, p = n.s.). In the present study, 7.7% of COPD patients met criteria for alcohol abuse and/or dependence. Although this rate was lower than reported by [@b46-copd-3-727], it was significantly higher compared with two reference samples ([@b50-copd-3-727]; [@b49-copd-3-727]).

As expected, only 4.9% of the patients had always been non-smokers, compared with 61.9% of the spouses. This difference is significant and cannot be explained by gender differences (females, Pearson's χ^2^ = 51.26, df = 2, p \< 0.001; males, Pearson's χ^2^ = 14.40, df = 2, p \< 0.001). The percentage of participants with clinically relevant SCL-90-R T-scores (ie, those with scores ≥ mean + 1 SD) was significantly higher in patients compared to spouses: somatization, 39.2% (vs 21.9%, Pearson's χ^2^ = 8.31, df = 1, p \< 0.004), depression (SCL-90-R), 29.4% (vs 16.2%, Pearson's χ^2^ = 5.80, df = 1, p \< 0.016), anxiousness, 25.2% (vs 15.2%, Pearson's χ^2^ = 3.61, df = 1, p \< 0.057), and phobic anxiety (SCL-90-R), 18.2% (vs 5.7%, Pearson's χ^2^ = 8.37, df = 1, p \< 0.004). There was a low but significant positive correlation between self-reported duration of illness and all SCL-90-R subscales -- even after controlling for age and FEV~1~% (partial correlation: somatization r~p~ = 0.24, depression r~p~ = 0.24, anxiousness r~p~ = 0.20, phobic anxiety r~p~ = 0.22; all p \< 0.05).

Quality of Life
---------------

It is important to note that the quality of life was considerably lower compared to the general 1 (EuroQol: CI = 76.3--77.1--77.9) in both patients (EuroQol: CI = 46.6--50.2--53.9) and spouses (EuroQol: CI = 62.6--66.5--70.5). COPD patients with mental disorders reported significantly higher scores on subscales for psychosocial impact (SGRQ-I) and health related quality of life (SGRQ-T) than patients without mental disorders (see [Table 3](#t3-copd-3-727){ref-type="table"}). There was no difference between COPD patients with and without mental disorders with regard to socio-demographic variables (age, gender), restriction of lung functioning (FEV~1~%), walking distance, or general health-related quality of life (EuroQol).

The nine variables (FEV~1~, walking distance, gender, heart disease, somatization, anxiousness, depression (SCL-90-R), phobic anxiety (SCL-90-R), depression/anxiety diagnoses), which had previously been identified as relevant predictors of health-related quality of life in patients with COPD, were included in a multiple regression model to predict health-related quality of life (SGRQ-T; [Table 4](#t4-copd-3-727){ref-type="table"}).

The present study identified 6 variables ([Table 4](#t4-copd-3-727){ref-type="table"}, model A, adjusted R^2^ = 0.64, p \< 0.001) as significant predictors of health-related quality of life. In a second regression analysis, spouse variables were included in addition to the above listed patient variables (model B, adjusted R^2^ = 0.62, p \< 0.001). The greatest proportion of variance in both models was explained by the patients' depression scores (SCL-90-R), walking distance (SWT), somatization, and male gender. In model B, spouses' anxiousness was a significant predictor of patients' health related quality of life, while the objective measures FEV~1~% and heart disease were not found to be significant predictors.

In addition, we analyzed whether the predictor variables from the first regression analysis (model A) would also predict spouses' perceived disability due to their partners' illness (criterion: S-CDI) ([Table 4](#t4-copd-3-727){ref-type="table"}). Twenty-seven percent of the variance (model C, adjusted R^2^ = 0.27, p \< 0.001) of the S-CDI was explained by the patient variables somatization, walking distance (SWT), and depression (SCL-90-R), again confirming the close relationship of the partner's well-being with patients' health.

In the fourth regression analysis psychosocial impact of the COPD patients in the SGRQ and the extent of other physical symptoms (P-somatization) predicted COPD-related disability in the spouses (model D, adjusted R^2^: 0.36, p \< 0.001).

Discussion
==========

The present study investigated the prevalence of mental disorders and quality of life in 143 consecutive COPD patients attending a private pulmonary practice as well as 105 spouses.

1.  Results revealed significantly increased prevalence rates for depressive disorders, anxiety disorders, and alcohol related disorders in COPD patients compared to a representative German reference sample ([@b50-copd-3-727]) and a German aging study ([@b10-copd-3-727]). Similarly, increased prevalence rates for depressive and anxiety disorders were found in patients' spouses.

    The high rates of alcohol abuse and dependence in patients in this study might be a result of more genuine response tendencies: during the screening of substance-related disorders -- and only at this point -- some of the spouses intervened and urged their partners to be more honest about the amount of alcohol consumption ([@b46-copd-3-727]).

2.  The second aim of this study was to investigate predictors of quality of life in COPD patients and their spouses. Results identified 6 out of 9 theoretically derived variables (somatization, depression \[SCL-90-R\], walking distance \[SWT\], gender, FEV~1~%, heart disease) as significant predictors of health-related quality of life in COPD patients. When including spouse variables, the objective variables (FEV~1~%, heart disease) failed to remain significant predictors for patients' quality of life, while symptoms of anxiousness in spouses explained substantial variance. This emphasizes the importance of spouses' anxiousness for the health-related quality of life in the patients.

3.  On the other hand, 36% of the total variance in spouses' COPD-related disability could be explained by disease-specific psychosocial impact (SGRQ-I) and the physical condition of the patients (somatization). This is a further indication that spouses of COPD patients are substantially affected by the disease of their partners, a fact that previous studies have already highlighted ([@b29-copd-3-727]; [@b27-copd-3-727]; [@b26-copd-3-727]; [@b41-copd-3-727]).

Limitations
-----------

Our study has several limitations. First, despite a comprehensive psycho-diagnostic assessment, the number of investigated diagnoses was limited in the present study. Second, some diagnostic criteria were difficult to evaluate in this patient group. For example, in order to receive a diagnosis of panic disorder, symptoms must not be due to a medical condition. In the case of patients with comorbid heart disease or severe dyspnea this is difficult to decide. Third, the cross-sectional design of this study does not allow conclusions to be drawn about the causal relationship between COPD, psychological disorders, and quality of life in the patients or psychological diagnoses and quality of life in the spouses. Furthermore, no conclusions can be drawn about the causal relation between patient variables and psychological disorders or quality of life in their spouses. Fourth, patients included in this study were stable out-patients at a private pulmonary practice. The present results may thus not be generalized to hospitalized patients or patients with acute exacerbation.

Implications
------------

### Diagnostic

The extensive diagnostic assessment according to ICD-10 was only conducted with respect to diagnoses which have frequently been investigated in COPD patients. It is likely that alcohol dependency is a comorbid disorder which so far has not received enough attention.

It is important to point out that a considerate number of patients who did not fulfil criteria for a current diagnosis reported having experienced severe symptoms of depression or anxiety on a few days in the past year (often during periods of COPD exacerbation). However, if a patient fulfils all symptoms necessary for a diagnosis of depression for only 9 days, a diagnosis of depression (ICD-10 F32) cannot be given. Similarly, in panic disorder (ICD-10 F41.0) symptoms must not be due a medical factor in order to meet diagnostic criteria. For a diagnosis of Generalized Anxiety Disorder (GAD), worries have to be disproportionate or unreasonable. In the present study, health-related worries did not count toward a diagnosis of GAD. This might account for the low prevalence rate of GAD in this study (5.6%) compared with 10%--15.8% ([@b52-copd-3-727]; [@b28-copd-3-727]; [@b1-copd-3-727]) found in former studies. The prevalence of GAD found in this sample might thus underestimate the scale of clinically relevant anxiety and worries.

Even if some of the reported symptoms did not meet diagnostic criteria for the above mentioned reasons, they still reflect clinically relevant psychopathology ([@b42-copd-3-727]). Such clinically relevant syndromes can be diagnosed according to ICD-10, for example as adjustment disorder, and anxiety or mood disorder due to a general medical condition ([Figure 1](#f1-copd-3-727){ref-type="fig"}).

The DSM-IV explicitly mentions COPD for anxiety disorder due to a medical condition ([@b18-copd-3-727]) and assumes that anxiety may be a direct result of the chronic hyperventilation pattern or of neurobiologically increased CO~2~ sensitivity ([@b13-copd-3-727]; [@b37-copd-3-727]). Therefore, these diagnoses should be considered more rigorously in future COPD studies.

### Intervention

Psychological disorders in patients should be treated pharmacologically and/or psychologically regardless of whether they are a direct consequence of the disease in the sense of an organic-related psychological disorder, an independent comorbid psychological disorder, or a reactive disorder. However, 70% of affected COPD patients refuse proposed pharmacological treatments ([@b55-copd-3-727]). This might be due to the large number of drugs already taken by such patients (on average 6.4, maximum of 17 in the present study).

Psychological interventions are often considered skeptically by patients and pneumologists. Hence it is important to point out the negative effects of increased anxiety or depression on the quality of life of COPD patients.

The high efficacy of cognitive--behavioral approaches in the treatment of anxiety disorders ([@b38-copd-3-727]) and depression disorders ([@b36-copd-3-727]) is beyond doubt. The efficacy of additional psychological interventions in patients with other somatic diseases, such as chronic pain ([@b23-copd-3-727]) or cancer ([@b39-copd-3-727]) has also been demonstrated.

The efficacy of psychological interventions in COPD patients with comorbid anxiety or depressive disorders is yet unclear ([@b5-copd-3-727]). There have only been a few studies with mostly small sample sizes. Two pilot studies ([@b35-copd-3-727]; [@b15-copd-3-727]) reported improved quality of life ([@b35-copd-3-727]) but no reduced levels of anxiety. In a controlled, randomized cognitive--behavioral study, a one-session short-term intervention could significantly reduce anxiousness and depression in COPD patients ([@b33-copd-3-727]). A small randomized controlled trial (RCT) ([@b9-copd-3-727]) showed significantly decreased depression and anxiety levels after psychotherapy (including cognitive-behavioral interventions). Cognitive Behavioral Group Therapy (CBT) in COPD patients with clinically significant symptoms of depression and anxiety resulted in a significant improvement of their quality of life ([@b31-copd-3-727]). CBT did not differ from COPD education, however, which also resulted in significant improvements regarding quality of life, anxiety und depression. In both treatment groups, improvements were maintained until follow-up. However, it is questionable whether there was sufficient time for individualized CBT interventions when using groups of 10 participants (8 × 60 minutes).

Thus, in addition to the conventional COPD education and comprehensive pulmonary rehabilitations, which are effective in the short term ([@b6-copd-3-727]), it is essential to establish appropriate short-term psychological interventions for COPD patients with psychological comorbidity by therapists trained in behavior medicine. Future research should therefore focus on the development and evaluation of effective psychological interventions for COPD patients with psychological comorbidities.

### Spouses

The finding that the spouses' anxiousness is a predictor for the health-related quality of life in patients underscores the importance of involving anxious spouses in intervention programs. Future studies will have to show whether this is a helpful tool to indirectly improve health-related quality of life in patients.

Further investigations and panel studies are needed to analyze the influence of other psychological factors (eg, satisfaction in the relationship, social support/distress, coping or avoidance of physical effort) on the quality of life of COPD patients.
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###### 

Sample characteristics

                       Patients (n = 143)                                              Spouses (n = 105)
  -------------------- -------------------------- ----------- ------------------------ --------------------------
  Age (years)          67.0 ± 9.5 range: 40--90                                        64.0 ± 9.3 range: 43--84
  Gender (F:M)         31:112 (21.7 : 78.3%)                                           19:86 (81.9 : 18.1%)
  Marital status                                                                       
   Single              8 (5.5%)                                                        
   Separated           11 (7.7%)                                                       
   Widowed             14 (9.8%)                                                       
   Married             110 (76.9%)                                                     105 (100%)
   Years of marriage   37.8 ±12.8                                                      range: 4--66
  Education                                                                            
   ≤9 years            110 (76.9%)                                                     86 (80.1%)
   10 years            19 (13.3%)                                                      14 (9.8%)
   13 years            14 (9.8%)                                                       5 (3.5%)
  COPD severity        FEV~1~% pred               SWT         Comorbid heart disease   
  2 n = 68 (47.6 %)    62.9 ± 9.6                 402 ± 241   n = 30 (44.1%)           
  3 n = 62 (43.4 %)    40.8 ± 5.3                 219 ± 161   n = 28 (45.2%)           
  4 n = 13 (9.1 %)     26.4 ± 2.8                 118 ± 133   n = 5 (38.5%)            

Data presented as n, mean ± SD

**Abbreviations:** FEV~1~% pred, forced expiratory volume in 1 second expressed in percentage predicted; SWT, shuttle walking test (in meters); comorbid heart disease, coronary heart disease, myocardial infarction or cardiac failure.

###### 

Comorbid mental disorders in COPD patients and their spouses

                                                      2 representative samples                 Significance Pearson's χ^2^               
  ------------------------------------ -------------- -------------------------- ------------- ----------------------------- ----------- -----------
  Anxiety/depression diagnoses:                                                                                                          
   Depressive disorder                 17 (11.9 %)    4.8 %                      1.1 %         18 (17.1 %)                   p \< .003   p \< .001
   Dysthymia                           3 (2.1 %)      2.0 %                      0.1 %         4 (2.8 %)                     n.s.        n.s.
   Panic disorder and/or agoraphobia   11 (7.7 %)     0.8 %                      0.5 %         5 (4.8 %)                     p \< .001   p \< .001
   Generalized anxiety disorder        8 (5.6 %)      0.9 %                      1.7 %         7 (6.7 %)                     p \< .001   p \< .001
  Alcohol dependence or harmful use:                                                                                                     
   At present                          11 (7.7 %)     1.2 %                      0.3 %         1 (1.0 %)                     p \< .001   n.s.
   Lifetime                            14 (9.8 %)                                              2 (2.0 %)                                 
   Non-existent                        118 (82.5 %)                                            102 (97.1 %)                              
  Nicotine dependence or abuse:                                                                                                          
   At present                          31 (21.7 %)    not assessed               23 (21.9 %)                                             
   Former smoker                       105 (73.4 %)                                            17 (16.2 %)                               
   Non-smoker                          7 (4.9 %)                                               65 (61.9 %)                               

**Abbreviations:** BASE, German Aging Study (data are DSM-III-R diagnoses according to [@b50-copd-3-727]); NMHWS, national mental health and well-being-survey (data according to [@b49-copd-3-727]).

###### 

Comparison of means in COPD patients with and without mental disorders

                                                           Patients with mental disorder (n = 28)   Patients without mental disorder (n = 115)                               
  -------------------------------------------------------- ---------------------------------------- -------------------------------------------- ------ ------ ------- ----- -------
  Gender[a](#tfn5-copd-3-727){ref-type="table-fn"} (F:M)   8 : 20                                   23 : 90                                                    n.s           
  Age (years)                                              67.0                                     9.6                                          64.0   9.3                  n.s.
  SWT                                                      298                                      221                                          297    227                  n.s.
  FEV~1~% pred                                             50.3                                     15.6                                         50.0   14.8                 n.s.
  SGRQ                                                                                                                                                                       
   Symptoms                                                57.7                                     25.1                                         63.8   22.9                 n.s.
   Activities                                              65.2                                     25.6                                         60.0   22.6                 n.s.
   Impact                                                  64.9                                     37.1                                         49.1   30.1   −2.37   141   0.010
   Total score                                             64.8                                     29.1                                         53.8   24.6   −2.04   141   0.022
  EuroQol[b](#tfn6-copd-3-727){ref-type="table-fn"}        43.9                                     29.5                                         51.8   19.9                 n.s.
  CDI                                                      5.27                                     2.83                                         4.25   2.86                 n.s.

Test statistics are t-tests, if not otherwise specified.

χ^2^;

Mann-Whitney U-Score.

**Abbreviations:** SWT, shuttle walking test; FEV~1~% pred, forced expiratory volume in 1 second expressed in percentage predicted; SGRQ, st. george's respiratory questionnaire; EuroQol, european quality of life questionnaire; CDI, COPD-disability-index.

###### 

Stepwise multiple linear regressions

  criterion: health-related quality of life in patients (SGRQ-T)                                                                                                                                                                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- --------- --------------------------------------------------------------------- -------------------------------------------- ---------
  Significant Predictors:                                                                                           [β](#tfn9-copd-3-727){ref-type="table-fn"}                                                                                    p         Significant Predictors:                                               [β](#tfn9-copd-3-727){ref-type="table-fn"}   p
  P-Depression (SCL-90-R)                                                                                           0.32                                                                                                                          \<0.001   P-Somatization[a](#tfn8-copd-3-727){ref-type="table-fn"} (SCL-90-R)   0.22                                         0.015
  Walking distance (SWT)                                                                                            −0.36                                                                                                                         \<0.001   Walking distance (SWT)                                                −0.53                                        \<0.001
  P-Somatization[a](#tfn8-copd-3-727){ref-type="table-fn"} (SCL-90-R)                                               0.27                                                                                                                          \<0.001   P-Depression (SCL-90-R)                                               0.30                                         \<0.001
  P-Gender (1 = F; 2 = M)                                                                                           0.14                                                                                                                          0.009     S-Anxiousness (SCL-90-R)                                              0.16                                         0.024
  FEV~1~% pred                                                                                                      −0.15                                                                                                                         0.014     P-Gender (1 = F; 2 = M)                                               0.14                                         0.028
  Heart disease                                                                                                     0.13                                                                                                                          0.027                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                               
  Excluded variables:                                                                                               Excluded variables:                                                                                                                                                                                                                                        
  SCL-90-R: P-Anxiousness, P-Phobic anxiety; P-depression/anxiety diagnoses                                         FEV~1~% pred; heart disease; S-Gender; SCL-90-R: S-Somatization, S-Depression, S-Phobic anxiety                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                               
  **criterion: COPD-related disability in spouses (S-CDI)**                                                                                                                                                                                                                                                                                                                    
  **Model C: patient variables from model A**                                                                       **Model D: patient variables from model C plus SGRQ scores**                                                                                                                                                                                               
  Significant Predictors:                                                                                           [β](#tfn9-copd-3-727){ref-type="table-fn"}                                                                                    p         Significant Predictors:                                               [β](#tfn9-copd-3-727){ref-type="table-fn"}   p
  P-Somatization[a](#tfn8-copd-3-727){ref-type="table-fn"} (SCL-90-R)                                               0.24                                                                                                                          0.057     Impact (SGRQ)                                                         0.46                                         \<0.001
  Walking distance (SWT)                                                                                            −0.36                                                                                                                         0.016     P-Somatization[a](#tfn8-copd-3-727){ref-type="table-fn"} (SCL-90-R)   0.22                                         0.024
  P-Depression (SCL-90-R)                                                                                           0.27                                                                                                                          0.020                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                               
  Excluded variables:                                                                                               Excluded variables:                                                                                                                                                                                                                                        
  SCL-90-R: P-Anxiousness, P-Phobic anxiety; P-Gender; P-depression/anxiety diagnoses; FEV~1~ pred; heart disease   SCL-90-R: P-Depression; Walking distance (SWT); FEV~1~% pred; heart disease; P-Gender; SGRQ: symptoms, activities; S-Gender                                                                                                                                

Scale without original items: chest pain/difficulties breathing

β = Stand. β --coefficient.

**Abbreviations:** FEV~1~% pred, forced expiratory volume in 1 second expressed in percentage predicted; SWT, shuttle walking test; SCL-90-R, symptom-checklist-90-R; SGRQ, st. george's respiratory questionnaire; P-..., patient variables; S-..., spouse variables.
